Time-to-event analyses of motor examination and functional outcomes in early Parkinson’s disease clinical trials

Clinical trials in early untreated Parkinson’s Disease risk confounding due to treatment initiation. Milder clinical features, functional preservation, and slow progression raise questions as to how meaningful benefit can be demonstrated before treatment begins. Time-to-event (TTE) outcomes may be valuable to detect benefit before treatment.

To explore the feasibility of detecting large, potentially more meaningful exam changes before treatment and how they correlate to functional outcomes, we analyzed four early interventional studies and one observational study over a 12-month period. Exam and functional worsening were assessed at varying thresholds using the Unified Parkinson’s Disease Rating Scale (UPDRS) or its Movement Disorders Society revision (MDS-UPDRS) Parts 2 and 3, respectively. At large thresholds, the percentage of persons achieving untreated worsening ranged from 32–42% on Part 2 ( ≥ 4 points) and 27–34% on Part 3 ( ≥ 7 points).

As thresholds were relaxed on Part 2 and Part 3, the proportion of participants achieving worsening increased across all cohorts. Many participants at each Part III threshold experienced simultaneous Part 2 worsening, with higher Part 3 thresholds generally associated with greater functional worsening. These TTE analyses in early PD trials support the feasibility of 12-month studies powered for large worsening thresholds in exam scores.

The authors are grateful to the participants, their families, investigators, and coordinators from the clinical trials analyzed in this work. This work was funded by ABLi Therapeutics, Inc. without a formal grant mechanism, and so has no associated grant number. The authors are grateful to PPMI, a public-private partnership funded by the Michael J.

Fox Foundation for Parkinson’s Research, and their funding partners, including those found at the following site: For up-to-date information on the study, visit. http://secure-web.cisco.com/1GfIQ-a8P5eVEqDGlQq1XVzm3E2w6KGRwHev86Kg7p0HZ0sLjHR4bNiacmJnDMXdwD0VICDL-TJcgKwc_s55gToQrr4Kbaom302BHWL4riA8GVZvFtKeqENdQS5EBfbviCFgqyoMskh8MYn9ljamI1f0qCkRsDDtkL2lP7-hCdeWokEdfMPV5nuyrYmdX5NpGxNUwnVQDVeQ3sc3_9x1aggorvDbq-9yCzJ88AJwRNTDyv3pYQ1M91GzaVNQn_ZNGLx96HZtTIpvHYh0I_NybofEz5Y8Yc6d0O98NOSZamZjBJdvACzyW1qbmb5IVobMO/http%3A%2F%2Fwww.ppmi-info.org. Clintrex Research Corporation, A Division of Blue Ridge Life Sciences, Houston, TX, USA Andrew McGarry, Karl Kieburtz & Jordan Dubow Cooper Medical School at Rowan University/Cooper University Healthcare, Camden, NJ, USA ABLi Therapeutics Inc., Atlanta, GA, USA University of Rochester School of Medicine, Rochester, NY, USA Correspondence to Andrew McGarry, Milton H. Werner or Charles Venuto.

The authors declare no competing interests. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material.